Fed’s Powell opens door to potential rate cuts at Jackson Hole
On Wednesday, Cantor Fitzgerald reaffirmed its confidence in Surgery Partners (NASDAQ:SGRY), maintaining an Overweight stock rating with a steady price target of $36.00. Currently trading at $23.05 with a market capitalization of $2.9 billion, the stock has shown notable volatility according to InvestingPro data. The firm’s analysis indicated that current trends within the company remain stable and additional data suggests a slowdown in hiring, which could be indicative of potential forthcoming deal announcements.
The research firm’s statement highlighted that despite the "deal noise," Surgery Partners has been consistently improving its fundamental business operations, with InvestingPro data showing revenue growth of 13.5% over the last twelve months. This improvement, combined with the company’s "GOOD" Financial Health score, supports the stance that the company’s stock is currently undervalued, presenting an attractive investment opportunity. Get access to 6 more exclusive InvestingPro Tips and comprehensive analysis in the Pro Research Report.
Surgery Partners, a healthcare services company that operates surgical facilities, has been under scrutiny by analysts tracking its performance and growth potential. While currently not profitable, InvestingPro analysis indicates that net income is expected to grow this year, with analysts forecasting positive earnings. The latest insights from Cantor Fitzgerald suggest that even with the potential slowdown in hiring, the company’s prospects remain positive.
The analyst from Cantor Fitzgerald, Sarah James, commented on the situation, stating, "We believe data support 1) our bullish thesis that SGRY is undervalued behind deal noise while it continues to improve fundamentals, or 2) SGRY is slowing down hiring ahead of announcing a deal. Either way, we view SGRY as an attractive opportunity."
Investors and market watchers will likely keep a close eye on Surgery Partners as it navigates its strategic moves in the healthcare industry. The maintained Overweight rating and price target signal a positive outlook for the company’s stock performance in the eyes of Cantor Fitzgerald.
In other recent news, Surgery Partners reported its first-quarter 2025 earnings, revealing a net revenue of $776 million, which represents an 8% increase year-over-year but fell slightly short of the expected $778.04 million. The company’s earnings per share (EPS) came in at $0.04, missing the forecasted $0.08. Despite this earnings miss, Surgery Partners reaffirmed its full-year 2025 guidance, projecting revenue between $3.3 billion and $3.45 billion and an adjusted EBITDA of $555 million to $565 million. Additionally, the company has invested $54 million in capital expenditures so far this year, indicating a return to more typical annual M&A investment levels.
In merger news, Bain Capital has made a nonbinding acquisition proposal for Surgery Partners, suggesting a potential buyout at $25.75 per share. This proposal highlights Bain’s interest in the company’s business and the ambulatory surgery center industry. Analyst firms have varied views on Surgery Partners, with KeyBanc maintaining a Sector Weight rating, reflecting a neutral stance, while Benchmark holds a Buy rating with a $35 price target, showing confidence in the company’s operational strategy and financial health. Leerink Partners has adjusted its price target to $34 from $36 but continues to rate the stock as Outperform, indicating positive expectations for the company’s future performance. These developments are crucial for investors monitoring Surgery Partners’ strategic direction and financial outlook.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.